Loading...
Contacts of persons with meningococcal disease usually receive prophylaxis with ciprofloxacin or rifampin. The MMWR reports three cases of fluoroquinolone-resistant Neisseria meningitidis in Minnesota and North Dakota in 2007 and early 2008.
The first case was a child in eastern North Dakota who became ill with meningitis in January 2007 and recovered fully. The second case was an adult in western Minnesota who died from meningococcal infection in early January 2008, and the third case was a college student from western Minnesota who developed headache, fever, and rash in late January 2008 and recovered completely. In all three cases, N. meningitidis was isolated from cerebrospinal fluid cultures and was found to be resistant to ciprofloxacin. Some contacts of these cases were treated with fluoroquinolones before antibiotic susceptibility results were available, and many subsequently were offered either rifampin or azithromycin. No contacts became ill.
Centers for Disease Control and Prevention (CDC). Emergence of fluoroquinolone-resistant Neisseria meningitidis — Minnesota and North Dakota, 2007–2008. MMWR Morb Mortal Wkly Rep 2008 Feb 22; 57:173.
Comment
This is the first report to describe fluoroquinolone-resistant meningococcal disease in North America. The Centers for Disease Control and Prevention (CDC) no longer recommends ciprofloxacin for prophylaxis of meningococcal disease in certain areas of Minnesota and North Dakota; rifampin, ceftriaxone, or azithromycin is recommended instead. Ciprofloxacin can still be used elsewhere, but the CDC and public health departments are monitoring for further emergence of resistance.